Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Panel OKs Free COVID-19 Vaccination for Ages 5-11, but No “Effort” Obligation Applied
A Japanese health ministry panel on February 10 approved the framework of COVID-19 vaccinations for children aged five through 11. While recommending such inoculations, the panel stopped short of imposing legal obligations on guardians to make their best efforts to…
To read the full story
Related Article
- Japan Panel Agrees to Vaccinate Children under Free COVID-19 Inoculation Program
January 27, 2022
- Japan to Import Pfizer’s Pediatric Vaccine Next Month, Inoculations to Begin in March: Minister
January 25, 2022
- Pfizer’s Comirnaty Bags Japan Approval for Ages 5-11; Actemra OK’ed for COVID-19
January 21, 2022
- Pfizer’s Comirnaty Clears Key Panel for Ages 5-11; Actemra Set for COVID-19 Nod
January 21, 2022
- Pfizer’s Comirnaty Up for PAFSC Review for Ages 5-11 on Jan. 20; Actemra to Add COVID-19 Use
January 14, 2022
- Chugai Files Actemra for COVID-19 Pneumonia in Japan
December 14, 2021
- Pfizer’s COVID-19 Vaccine Filed for Children 5 to 11 in Japan
November 10, 2021
REGULATORY
- Trump Signs Off on Up to 100% Tariffs on Drugs; Japan Rate Set at 15%
April 3, 2026
- Japan Launches Task Force to Secure Critical Supplies amid Middle East Crisis
April 3, 2026
- MHLW Streamlines Lot Release Procedures for Vaccines, Blood Products
April 3, 2026
- MHLW Allows Outer Packaging Labeling for Regenerative Medicine Products
April 3, 2026
- MHLW’s Drug Supply Monitoring System Now Up and Running
April 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…